Moneycontrol PRO
you are here: HomeNewsOpinion

Glenmark rides COVID-19 wave, all eyes on debt reduction

Glenmark's revenue in India grew about 11 percent in nine months to December 2020 compared to a less than 1 percent expansion in industry sales during the same time

April 07, 2021 / 09:34 AM IST
Glenmark rides COVID-19 wave, all eyes on debt reduction

Glenmark Pharmaceuticals did well to move quickly on the COVID-19 opportunity. It was the first company in India to receive the regulatory approval for oral antiviral medication drug Favipiravir to treat mild to moderate COVID-19. The drug helped the company to maintain sales momentum in India even as the pandemic weighed on the industry’s growth. Thanks to its early launch Glenmark's Favipiravir continued to have a large market share. Glenmark’s revenue in India grew about 11 percent in nine months till December 2020...

  • PRO Panorama

    Moneycontrol Pro Panorama | Robinhood missed the mark on a bumper listing

    Jul 30, 2021 / 04:26 PM IST

    In today’s edition of Moneycontrol Pro Panorama:  Why Robinhood stumbled, the problem with IMF forecasts, the Immunity Tracker, Tech Mahindra’s growth appeal, Tactical Pick, the Indian startup rage, China pushes back on crypto and more  

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers